Answers are grounded in this paper and cite their sources.
Human T-cell leukemia virus type 1 (HTLV-1) is a neglected retrovirus that causes adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite an estimated 5–10 million worldwide infections, surveillance remains limited, particularly among underserved United States (U.S.) populations. This report examines disparities in HTLV-1 research, diagnosis, and care across populations from endemic regions and their U.S. diasporas. Jamaica, Haiti, and Trinidad & Tobago report seroprevalence rates of 1–6%, yet surveillance has declined since the early 2000s. Elevated ATLL incidence among Caribbean-born U.S. residents indicates substantial disease burden despite the absence of population-based HTLV-1 surveillance. Japan’s national antenatal screening programs have reduced transmission, while the United States lacks comparable frameworks. HTLV-1 prevalence among U.S. Pacific Islander populations remains insufficiently characterized, and demographic aggregation limits population assessment. Limited surveillance and barriers to diagnosis leave important uncertainties about the distribution of HTLV-1 infection and associated disease in the United States; ancestry and demographic concentration alone cannot resolve these uncertainties. Drawing on international experience, this report proposes integrating low-cost diagnostics, community-led outreach, and equitable clinical trial participation to improve detection and outcomes. HTLV-1 thus represents not only an infectious disease gap but a marker of enduring global and domestic health inequities.
No takes yet. Share an insight, caveat, or question.
Hoffmann et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: